BACKGROUND: Borderline ovarian tumor (BOT) is an epithelial ovarian tumor with atypical epithelial proliferation without stromal invasion. BOTs may have an aggressive fashion with associated microinvasion feature, peritoneal “implants,” regional lymphadenopathy, and higher International Federation of Gynecology and Obstetrics (FIGO) stage. CD133 is cancer stem cells (CSCs) marker that promotes cell proliferation and tumor invasion through induction of nuclear factor kappa B and upregulation of MMP9. Aldehyde dehydrogenase 1A1 (ALDH1A1) is CSCs marker that promotes cell proliferation through the upregulation of c-MYC and cyclin-D1. AIM: The aim of this study was to investigate the correlation between CD133 and ALDH1A1 expression with FIGO stage. This research was performed as an analytic-observational with a cross-sectional design. METHODS: This research using a paraffin block of patients diagnosed as BOT in Hasan Sadikin Hospital Bandung. Samples were divided in two groups: FIGO stage IA and FIGO stage >IA. All samples were stained by immunohistochemistry CD133 and ALDH1A1. All data were analyzed using the Chi-square test with a significant level 5%. RESULTS: This study showed a statistically significant correlation between CD133 (p = 0.047) and ALDH1A1 (p = 0.042) expression with FIGO stage in BOT. Multivariate analysis showed there was no correlation between CD133 and ALDH1A1 in the affected of FIGO stage in BOT. CONCLUSION: CD133 and ALDH1A1 in BOT can be considered as a factor to predict the prognosis of BOT through predict FIGO stage.
Ovarian cancer (OC) is the fifth most common cancer in women and has become the main cause of gynecologic malignancy death. The incidence rate of OC increase and overall survival (OS) is relatively low because most of patients are diagnosed at advanced stages. Serous ovarian cancer (SOC) is the most frequent histopathological type and often occurs at late stage. Stage and optimal treatment are independently associated with chemo-response in SOC. FIGO staging system in SOC can provide prognostic information and guidance on personalized management of ovarian cancer. Cancer stem cells (CSC) are pivotal players in SOC progression and prognosis. CD133 and ALDH1A1 are related CSC markers in SOC. This study aimed to investigate the expression of CD133 and ALDH1A1 in SOC and their correlation with FIGO stage. This research was carried out as analytic-observational with cross-sectional design using paraffin block of patients diagnosed with SOC in the Department of Anatomic Pathology Hasan Sadikin Hospital Bandung. Samples were divided in two groups: early stage (FIGO stage I and II) and advanced stage (FIGO stage III and IV). All samples were stained by immunohistochemistry CD133 and ALDH1A1. All data were analysed using Chi-Square test with significant level 5%. The results of this study showed that there was correlation between expression of CD133 with FIGO staging in SOC (p value 0.004) and there was no correlation between expression of ALDH1A1 with FIGO staging in SOC (p value 0.197). It can be concluded that higher CD133 expression showed higher tumour cells ability to do invasion and metastasis and had higher influenced FIGO stage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.